Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 12, 1998

View Archived Issues

Bone Care International: Q3 1998 highlights

Guilford: Q3 1998 highlights

Genzyme Transgenics: Q3 1998 highlights

Ono: Annual Report 1998

Levosimendan clinical results presented this week at AHA meeting

S-18127 characterized as a selective, structurally novel 5-HT1B/1D receptor antagonist

Team from Angiotech demonstrates paclitaxel's potential as an antipsoriatic

KGF-2 shows promise for treating IBD

ETA antagonist has positive effects on pulmonary vascular resistance in patients with HF

Heptazyme demonstrates potent activity against HCV

FDA grants priority review status to Zila's NDA for OraTest

NOS-inhibitory condensed piperidines disclosed by Ono

Patent covers selective COX-2 inhibitors for relieving pain, fever and inflammation

Compounds for influenza developed at Shionogi

Protein tyrosine kinase inhibitors for cancer, polycystic kidney disease

Preparation and use of new CNS-active series reported by Pharmacia & Upjohn

New mechanism of action described for immunomodulating agent OM-89

First clinical results published for HIV fusion inhibitor

Pharmacological profile of the novel, selective kappa-opioid agonist HZ2

Small-molecule FGFR-1 tyrosine kinase inhibitor with nanomolar potency and good selectivity

NK2 antagonist from Zeneca blocks increased pulmonary resistance in guinea pigs

Pharming to begin phase II trial of new Pompe's disease therapy

SPBN: a free radical scavenger with potential in pediatric head trauma

Evidence of cardiac valve abnormalities in Redux-treated patients still controversial

Favorable phase III trial results presented for Evacet at ESMO; company prepares NDA

First IND filed by Avigen for hemophilia B gene therapy

Phase III trials with inhaled insulin begin in type I and II diabetics

First clinical results reported for novel gene therapy in coronary artery disease

Positive phase III clinical trial results received for Olux

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...